Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    2 days ago
    Change Detected
    Summary
    Added a new press release entry for 10 April 2026 about Alexion data at the 2026 AAN Annual Meeting. Removed the 03 February 2026 update on Saphnelo subcutaneous administration in systemic lupus erythematosus.
    Difference
    0.9%
    Check dated 2026-04-11T10:44:51.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    Added two press releases: EMERALD-3 trial results for Imfinzi plus Imjudo with lenvatinib and TACE (02 April 2026) and Efzimfotase alfa Phase III results in hypophosphatasia (31 March 2026). Deleted two items: Imfinzi perioperative regimen recommended for EU approval by CHMP (02 February 2026) and AstraZeneca begins trading on the New York Stock Exchange.
    Difference
    5%
    Check dated 2026-04-04T06:14:52.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    Added a new press release about Tozorakimab meeting primary endpoints in COPD Phase III trials (27 March 2026); removed the January 30, 2026 CSPC collaboration press release from the list.
    Difference
    0.9%
    Check dated 2026-03-28T03:42:31.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    A new press release item dated 16 March 2026 about Imfinzi being approved in the EU was added. A January 29, 2026 investment announcement in China was removed.
    Difference
    0.9%
    Check dated 2026-03-21T01:06:06.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    Added a press release dated 09 March 2026 about Enhertu Priority Review for HER2-positive early breast cancer; removed the 20 January 2026 press release about completing a direct NYSE listing.
    Difference
    0.9%
    Check dated 2026-03-13T20:56:24.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    Added Feb 20, 2026 press release: Calquence plus venetoclax approved in the US for first-line chronic lymphocytic leukaemia. Removed Jan 8, 2026 press release announcing Joris Silon as Head of Investor Relations.
    Difference
    0.9%
    Check dated 2026-02-20T15:25:18.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.